Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EIF4A1 | P60842 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732903 | 0.82 | CA1 (0.42) | RAB9ANPC1MAPTMAPK1KMT2A | |
| SCHEMBL4397640 | 0.82 | SIGMAR1 (0.43) | RAB9AKMT2AEDNRAALDH1A1SIGMAR1 | |
| Potassium Ion SCHEMBL9283665 | 0.77 | NFKB1 (0.34) | RAB9ANPC1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL14967746 | 0.69 | EDNRA (0.40) | RAB9ANPC1MAPTMAPK1KMT2A | |
| SCHEMBL28533814 | 0.69 | ALDH1A1 (0.45) | MAPTEDNRAALDH1A1EDNRBBACE1 | |
| SCHEMBL5727679 | 0.69 | RECQL (0.40) | ALDH1A1TSHRCACNA1D | |
| Tert-Butyl Formate SCHEMBL28532950 | 0.68 | ALDH1A1 (0.39) | RAB9ANPC1MAPTMAPK1KMT2A | |
| SCHEMBL16247216 | 0.68 | CHRNA7 (0.42) | MAPTKMT2AEDNRAALDH1A1TSHR | |
| SCHEMBL14967648 | 0.67 | BACE1 (0.36) | RAB9ANPC1MAPTMAPK1KMT2A | |
| SCHEMBL8859269 | 0.67 | CYP2D6 (0.37) | MAPTMAPK1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020038038-A1 | Methods for treating pathological conditions of abnormal cell proliferation | AVENTIS PHARMA S.A. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038038-A1 | Methods for treating pathological conditions of abnormal cell proliferation | MKI67, MCL1, ACIN1 | RAB9A 2665/4885NPC1 1617/4885MAPT 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.